References: 1. Rush AJ. Unipolar major depression in adults: Choosing initial treatment. Nov 28, 2022. Accessed June 26, 2023. Available from https://www.uptodate.com/contents/unipolar-major-depressionin-adults-choosing-initial-treatment 2. Rush AJ. Unipolar depression in adults and initial treatment: General principles and prognosis. May 26, 2021. Accessed June 26, 2023. Available from https://www.uptodate. com/contents/unipolar-depression-in-adults-and-initial-treatment-general-principles-and-prognosis 3. Serlife® 50 mg and 100 mg tablets professional information, March 2021. 4. Rush AJ. Patient education: Depression treatment options for adults (Beyond the Basics). July 25, 2022. Accessed June 26, 2023. Available from https://www.uptodate.com/contents/depression-treatment-options-for-adults-beyond-thebasics 5. National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. June 29, 2022. Accessed June 27, 2023. Available from https://www.nice.org.uk/guidance/ ng222 S5 SERLIFE® 50 (Film-coated tablets). Reg. No.: 36/1.2/0272. Each film-coated tablet contains sertraline hydrochloride equivalent to sertraline 50 mg. Sugar free. S5 SERLIFE® 100 (Film-coated tablets). Reg. No.: 36/1.2/0273. Each film-coated tablet contains sertraline hydrochloride equivalent to sertraline 100 mg. Sugar free. Pharmacological classification: A 1.2 Psychoanaleptics (Antidepressants). For full prescribing information, refer to the Professional Information Leaflet approved by the Regulatory Authority. Applicant: Ranbaxy Pharmaceuticals (Pty) Ltd, 14 Lautre Road, Stormill, Ext.1, Roodepoort, 1724. Tel: +27 11 495-0100. Fax: +27 12 495-0150. www.sunpharma.com